[go: up one dir, main page]

AR041037A1 - Uso terapeutico n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida - Google Patents

Uso terapeutico n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida

Info

Publication number
AR041037A1
AR041037A1 ARP030103041A ARP030103041A AR041037A1 AR 041037 A1 AR041037 A1 AR 041037A1 AR P030103041 A ARP030103041 A AR P030103041A AR P030103041 A ARP030103041 A AR P030103041A AR 041037 A1 AR041037 A1 AR 041037A1
Authority
AR
Argentina
Prior art keywords
cancer
oxadiazol
sulfonamide
phenyl
methylpirazin
Prior art date
Application number
ARP030103041A
Other languages
English (en)
Inventor
Marianne Ashford
Nigel Barras
Francis Boyle
Andrew Hughes
Donna Johnstone
Sina Taylor
David Tonge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR041037(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR041037A1 publication Critical patent/AR041037A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe el uso de N-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida, o una sal de la misma aceptable para uso farmacéutico, en el tratamiento del cáncer y/o el dolor de un animal de sangre caliente, tal como el hombre. Reivindicación 6: El uso de acuerdo con cualquiera de las reivindicaciones 1,caracterizado porque el cáncer es cáncer de esófago, mieloma, hepatocelular, pancreático, cáncer cervical, tumor de Ewings, neuroblastoma, sarcoma de Kaposi, cáncer de ovario, cáncer de mama, cáncer colorrectal, cáncer de próstata, cáncer de vejiga, melanoma, cáncer de pulmón - cáncer de células no pequenas de pulmón (NSCLC) y cáncer de células pequenas de pulmón (SCLC), cáncer gástrico, cáncer de cabeza y cuello, cáncer renal, linfoma y leucemia.
ARP030103041A 2002-08-23 2003-08-22 Uso terapeutico n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida AR041037A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0219660.8A GB0219660D0 (en) 2002-08-23 2002-08-23 Therapeutic use

Publications (1)

Publication Number Publication Date
AR041037A1 true AR041037A1 (es) 2005-04-27

Family

ID=9942847

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103041A AR041037A1 (es) 2002-08-23 2003-08-22 Uso terapeutico n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida

Country Status (32)

Country Link
US (2) US7820679B2 (es)
EP (2) EP1545710B1 (es)
JP (2) JP3663202B2 (es)
KR (1) KR20050035280A (es)
CN (1) CN100467023C (es)
AR (1) AR041037A1 (es)
AT (1) ATE427773T1 (es)
AU (1) AU2003255835B8 (es)
BR (1) BR0313655A (es)
CA (1) CA2496476C (es)
CL (1) CL2003001692A1 (es)
CY (1) CY1110712T1 (es)
DE (1) DE60327084D1 (es)
DK (1) DK1545710T3 (es)
ES (1) ES2323309T3 (es)
GB (1) GB0219660D0 (es)
HK (1) HK1077534A1 (es)
IL (1) IL166730A0 (es)
IS (1) IS2704B (es)
MX (1) MXPA05001862A (es)
MY (2) MY136449A (es)
NO (1) NO330756B1 (es)
NZ (1) NZ538114A (es)
PL (1) PL375561A1 (es)
PT (1) PT1545710E (es)
RU (1) RU2340343C2 (es)
SA (1) SA03240363B1 (es)
SI (1) SI1545710T1 (es)
TW (1) TWI302912B (es)
UA (1) UA82071C2 (es)
WO (1) WO2004018044A2 (es)
ZA (1) ZA200501267B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
WO2007111350A1 (ja) * 2006-03-28 2007-10-04 Osaka Bioscience Institute 血管新生ならびに癌細胞のmesenchymal型およびamoeboid型浸潤を阻害するための薬剤
US20090062246A1 (en) * 2007-08-17 2009-03-05 Astrazeneca Ab Therapeutic treatment-014
DK2209501T3 (da) * 2007-10-12 2012-02-27 Astrazeneca Ab Zibotentan-sammensætning, der indeholder mannitol og mikrokrystallinsk cellulose
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
WO2010004337A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab Combinations comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2- (4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and pemetrexed
SG194847A1 (en) * 2011-05-17 2013-12-30 Plexxikon Inc Kinase modulation and indications therefor
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
KR101855382B1 (ko) * 2015-12-31 2018-05-04 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 예방, 치료 및 전이 억제용 약학적 조성물

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (es) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (es) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
WO1999048530A1 (en) 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
DK1121111T3 (da) 1998-10-15 2010-05-31 Imp Innovations Ltd Forbindelser til behandling af vægttab
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
AU2092601A (en) * 1999-12-15 2001-06-25 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
AU2000279614A1 (en) 2000-02-16 2001-08-27 Yamanouchi Pharmaceutical Co., Ltd Remedies for endothelin-induced diseases
EP1289558A2 (en) 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
WO2002049630A2 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
MXPA03007960A (es) 2001-03-06 2003-12-04 Cellegy Pharma Inc Compuestos y metodos para el tratamiento de desordenes urogenitales.
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
CA2442591A1 (en) 2001-04-11 2002-10-31 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
ATE498408T1 (de) 2001-08-10 2011-03-15 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
DE10155076A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
WO2005063735A1 (de) 2003-12-20 2005-07-14 Merck Patent Gmbh 2- (hetero) -arylsubstituierte tetrahydrochinolinderivate
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
WO2004018044A2 (en) 2004-03-04
MY137595A (en) 2009-02-27
DK1545710T3 (da) 2009-06-29
HK1077534A1 (en) 2006-02-17
CA2496476A1 (en) 2004-03-04
US20110003831A1 (en) 2011-01-06
GB0219660D0 (en) 2002-10-02
ATE427773T1 (de) 2009-04-15
JP2004083590A (ja) 2004-03-18
JP2005097312A (ja) 2005-04-14
EP1545710A2 (en) 2005-06-29
PL375561A1 (en) 2005-11-28
IS2704B (is) 2010-12-15
MY136449A (en) 2008-10-31
ZA200501267B (en) 2006-10-25
WO2004018044A8 (en) 2004-06-24
NO330756B1 (no) 2011-07-04
RU2005108349A (ru) 2005-08-27
IS7766A (is) 2005-03-22
ES2323309T3 (es) 2009-07-13
MXPA05001862A (es) 2005-06-03
WO2004018044A3 (en) 2004-05-06
US7820679B2 (en) 2010-10-26
EP1545710B1 (en) 2009-04-08
DE60327084D1 (de) 2009-05-20
AU2003255835B2 (en) 2007-04-05
EP2072082A3 (en) 2009-12-23
TWI302912B (en) 2008-11-11
UA82071C2 (en) 2008-03-11
JP3663202B2 (ja) 2005-06-22
NZ538114A (en) 2008-02-29
IL166730A0 (en) 2006-01-15
PT1545710E (pt) 2009-05-26
BR0313655A (pt) 2005-06-21
KR20050035280A (ko) 2005-04-15
AU2003255835B8 (en) 2007-05-17
AU2003255835A1 (en) 2004-03-11
CN1688365A (zh) 2005-10-26
CL2003001692A1 (es) 2005-01-21
SI1545710T1 (sl) 2009-08-31
CY1110712T1 (el) 2015-06-10
CA2496476C (en) 2009-08-04
SA03240363B1 (ar) 2009-04-11
RU2340343C2 (ru) 2008-12-10
US20060094729A1 (en) 2006-05-04
EP2072082A2 (en) 2009-06-24
CN100467023C (zh) 2009-03-11
TW200409768A (en) 2004-06-16
NO20050689L (no) 2005-03-21

Similar Documents

Publication Publication Date Title
RU2441005C2 (ru) Новые пиразолопиримидины как ингибиторы циклинзависимых киназ
LU92155I2 (fr) Crizotinib, éventuellement sous la forme d'un sel,hydrate ou solvate pharmeceutiquement acceptable
DOP2012000153A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes
HUP0301512A2 (hu) Gyomor-bél csatornában fellépő kötőszöveti váz tumorok kezelése
AR041037A1 (es) Uso terapeutico n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida
CY1115571T1 (el) Νεες ενωσεις και μεθοδοι για θεραπεια
NZ561609A (en) 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
MY137156A (en) Dual nk1/nk3 derivatives
HK1062888A1 (en) Vinyl phenyl derivatives as glk activators
PE20220569A1 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y metodos de tratamiento con dichos compuestos
CY1111670T1 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
DE602004024375D1 (de) Carboxamidderivate
SE0102300D0 (sv) Compounds
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
EA200401114A3 (ru) Замещённые гидроксиэтиламины
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
DE60045508D1 (de) Dalda-analoge und ihre verwendung
NO20060361L (no) Nye cytotoxiske depsipeptider
MY141583A (en) Novel fused heterocycles and uses thereof
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
RU2014122867A (ru) Способ лечения рака иммунотерапевтическим средством, специфичным в отношении MAGEA3, совместно с ингибитором BRAF и/или ингибитором MEK
DE602004030265D1 (de) Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin
DE602004019939D1 (de) Thiazolderivate als npy-antagonisten
RU2007132976A (ru) Производные пиразолиламинопиридина, пригодные в качестве ингибиторов киназы
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей

Legal Events

Date Code Title Description
FB Suspension of granting procedure